secwatch.observer — SEC 8-K summary
======================================

Issuer:     EVOME MEDICAL TECHNOLOGIES INC. (—)
CIK:        0001617765
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001062993-24-007571
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evome Medical posts FY2023 preliminary revenue C$62.6M, positive Adj EBITDA C$852K
--------------------------------------------------------------------------------

- Revenue C$62.6M, gross margin C$22.5M (36% of sales); Adjusted EBITDA positive C$852K.
- CEO Seckler states turnaround completed after H1 losses; two consecutive quarters of positive Adj EBITDA.
- Full FY2023 financial statements (10-K) to be filed April 16, 2024.
- Plans to reduce debt by divesting non-core units; launched RST product; SpaceTek Knee expected late 2024.
- Fourth-quarter strength drove full-year positive EBITDA; first quarter 2024 improvements continuing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617765/000106299324007571/0001062993-24-007571-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617765/000106299324007571/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-24-007571

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer